Biocartis to Develop EGFR Mutation Test to Further Home in on Best Responders to EGFR Inhibitors | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biocartis today announced that it has licensed from Hospital del Mar in Spain the rights to an EGFR biomarker for colon cancer.

The Lausanne, Switzerland-based firm plans to develop an EGFR mutation test that can help doctors further refine the best responder population among colon cancer patients receiving EGFR inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.